See the difference! Customize Seeking Alpha:
Sign in or join
Seeking Alpha
Home
The Macro View
Stocks & Sectors
Global Markets
ETFs
Investing Ideas
Breaking News
Transcripts
Business Intelligence
Athersys, Inc. (ATHX)
(
)
Quotes
Dashboard
Chart
Historical Prices
Options
Analysis
Articles
Instablogs
StockTalks
Sentiment
Comments
News & PR
Market Currents
Buzz
Twitter: ATHX
Coverage
Top Authors
Cramer
Top Analysts
Business Intelligence
Transcripts
Events
Key Developments
Earnings
History & Projected
Consensus
Peer Earnings
Filings
SEC Filings
Annual Report
Ownership
Major Holders
Insider Trades
Insider Sentiment
Index Membership
Short Interest
Financials
Income Statement
Balance Sheet
Cash Flow
Company
Wikipedia Profile
Officers & Directors
Executive Comp
Market Currents
Monday, December 21, 2009
09:48 AM
Athersys (ATHX)
+200%
after
inking a deal with Pfizer
(PFE) to develop and market its experimental stem cell therapy MultiStem. Pfizer will pay $6M up front, fund the drug's R&D, and pay up to $105M on milestones.
Comment!